Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naive HIV-1 positive subjects commencing Antiretroviral Therapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abacavir (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Raltegravir (Primary) ; Rilpivirine (Primary) ; Ritonavir (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary)
Indications HIV-1 infections
Focus Biomarker; Pharmacodynamics
Acronyms BIGgeR

20 Nov 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
29 Nov 2022 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
29 Nov 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com